2011 年的膀胱癌：个性化医疗的曙光。
Bladder cancer in 2011: the dawn of personalized medicine.
机构信息
University of Colorado Comprehensive Cancer Center, 1665 Aurora Court, Aurora, CO 80045, USA.
出版信息
Nat Rev Urol. 2011 Dec 20;9(2):65-6. doi: 10.1038/nrurol.2011.220.
Abstract
Long awaited data from the clinical investigation of bladder cancer in both the neoadjuvant and adjuvant settings were released in 2011, setting the stage for the next generation of work in this area. The findings of a number of studies provide the first steps towards a personalized approach to this disease.
摘要
2011 年公布了膀胱癌新辅助和辅助治疗临床研究的期待已久的数据，为该领域的下一代工作奠定了基础。多项研究的发现为针对这种疾病的个体化方法迈出了第一步。
相似文献
1
Bladder cancer in 2011: the dawn of personalized medicine.2011 年的膀胱癌：个性化医疗的曙光。
Nat Rev Urol. 2011 Dec 20;9(2):65-6. doi: 10.1038/nrurol.2011.220.
2
New strategies in muscle-invasive bladder cancer: on the road to personalized medicine.肌层浸润性膀胱癌的新策略：迈向个体化医学之路。
Clin Cancer Res. 2011 May 1;17(9):2608-12. doi: 10.1158/1078-0432.CCR-10-2770. Epub 2011 Mar 17.
3
Operationalizing Precision Cardiovascular Medicine: Three Innovations.精准心血管医学的实践：三项创新。
Circ Res. 2016 Oct 14;119(9):984-987. doi: 10.1161/CIRCRESAHA.116.309776.
4
The innovative therapies that could break the brain-cancer stalemate.有望打破脑癌治疗僵局的创新疗法。
Nature. 2018 Sep;561(7724):S59-S61. doi: 10.1038/d41586-018-06713-6.
5
Individualized management of advanced bladder cancer: Where do we stand?晚期膀胱癌的个体化管理：我们目前的进展如何？
Urol Oncol. 2015 Apr;33(4):187-95. doi: 10.1016/j.urolonc.2013.09.019. Epub 2013 Dec 12.
6
Precision medicine for managing diabetes.糖尿病管理的精准医学
J Diabetes Sci Technol. 2015 Jan;9(1):3-7. doi: 10.1177/1932296814563643.
7
Comparative clinical trials with a novel approach: Utilizing the shiny method for investigational urothelial carcinoma therapies.采用新方法的比较性临床试验：利用闪亮方法进行尿路上皮癌治疗研究
Int J Urol. 2024 Oct;31(10):1168-1170. doi: 10.1111/iju.15528. Epub 2024 Jul 1.
8
Primary central nervous system lymphoma: Novel precision therapies.原发性中枢神经系统淋巴瘤：新型精准治疗方法。
Crit Rev Oncol Hematol. 2019 Sep;141:139-145. doi: 10.1016/j.critrevonc.2019.06.009. Epub 2019 Jun 27.
9
The frontier of tDCS in psychiatry and the role of new technologies.经颅直流电刺激在精神病学中的前沿进展及新技术的作用。
Encephale. 2019 Jun;45 Suppl 2:S55-S57. doi: 10.1016/j.encep.2019.04.004. Epub 2019 May 11.
10
Emerging personalized approaches for the management of advanced urothelial carcinoma.新兴的个性化方法用于晚期尿路上皮癌的治疗。
Expert Rev Anticancer Ther. 2012 Dec;12(12):1537-43. doi: 10.1586/era.12.141.
引用本文的文献
1
The importance of personalized medicine in urological cancers.个性化医疗在泌尿生殖系统癌症中的重要性。
J Diabetes Metab Disord. 2021 Jun 29;21(1):841-852. doi: 10.1007/s40200-021-00824-0. eCollection 2022 Jun.
2
The New Age of -omics in Urothelial Cancer - Re-wording Its Diagnosis and Treatment.尿路上皮癌的组学新纪元——重新定义其诊断与治疗
EBioMedicine. 2018 Feb;28:43-50. doi: 10.1016/j.ebiom.2018.01.044. Epub 2018 Feb 2.
3
Patient Mutation Directed shRNA Screen Uncovers Novel Bladder Tumor Growth Suppressors.患者突变导向的shRNA筛选揭示新型膀胱肿瘤生长抑制因子
Mol Cancer Res. 2015 Sep;13(9):1306-15. doi: 10.1158/1541-7786.MCR-15-0130. Epub 2015 Jun 15.
4
Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance.阻断前列腺素E2诱导的肿瘤再增殖可消除膀胱癌的化疗耐药性。
Nature. 2015 Jan 8;517(7533):209-13. doi: 10.1038/nature14034. Epub 2014 Dec 3.
本文引用的文献
1
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder.膀胱移行细胞癌中染色质重塑基因的频繁突变。
Nat Genet. 2011 Aug 7;43(9):875-8. doi: 10.1038/ng.907.
2
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status.基于 p53 状态的局部晚期膀胱癌分子靶向辅助治疗的 III 期研究。
J Clin Oncol. 2011 Sep 1;29(25):3443-9. doi: 10.1200/JCO.2010.34.4028. Epub 2011 Aug 1.
3
International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.评估新辅助顺铂、甲氨蝶呤和长春碱化疗治疗肌层浸润性膀胱癌的国际 III 期临床试验：BA0630894 试验的长期结果。
J Clin Oncol. 2011 Jun 1;29(16):2171-7. doi: 10.1200/JCO.2010.32.3139. Epub 2011 Apr 18.
4
Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.顺铂、吉西他滨和贝伐珠单抗一线治疗转移性尿路上皮癌的 II 期临床试验：印第安纳大学肿瘤学组 GU04-75。
J Clin Oncol. 2011 Apr 20;29(12):1525-30. doi: 10.1200/JCO.2010.31.6067. Epub 2011 Mar 21.
5
A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment.一个用于膀胱癌分子淋巴结分期的 20 基因模型：开发和前瞻性评估。
Lancet Oncol. 2011 Feb;12(2):137-43. doi: 10.1016/S1470-2045(10)70296-5. Epub 2011 Jan 20.
6
Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer.肿瘤内皮素-1 增强膀胱癌小鼠异种移植模型中肺的转移定植。
J Clin Invest. 2011 Jan;121(1):132-47. doi: 10.1172/JCI42912. Epub 2010 Dec 22.
7
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.新辅助化疗联合膀胱切除术与单纯膀胱切除术治疗局部晚期膀胱癌的比较。
N Engl J Med. 2003 Aug 28;349(9):859-66. doi: 10.1056/NEJMoa022148.
8
p53 and chemosensitivity.p53与化疗敏感性
Ann Oncol. 1999 Sep;10(9):1011-21. doi: 10.1023/a:1008361818480.
9
Accumulation of nuclear p53 and tumor progression in bladder cancer.细胞核p53的积累与膀胱癌的肿瘤进展
N Engl J Med. 1994 Nov 10;331(19):1259-64. doi: 10.1056/NEJM199411103311903.
Zotero 插件